Physician profile
Katrina Smith
NPI 1851696025
$2,682.11
in general payments reported to CMS, 2019-2025
21 companies · $232 in 2025
The $232 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $371 · 2022: $791 · 2023: $436 · 2024: $852 · 2025: $232.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,520.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,519.52 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $339.99 | 2021-2022 | |
| Amgen INC. | $271.98 | 2023-2024 | Repatha |
| Neurocrine Biosciences, INC. | $256.54 | 2022 | |
| Abbvie INC. | $217.05 | 2022-2023 | |
| Abbott Laboratories | $140.11 | 2023 | Thoratec Heartmate 3 Lvas Implant Kit |
| Biohaven Pharmaceuticals, INC. | $124.34 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $122.13 | 2024 | |
| Boston Scientific Corporation | $122.04 | 2021 | |
| Regeneron Healthcare Solutions, INC. | $121.84 | 2024 | Evkeeza |
| Teva Pharmaceuticals USA, INC. | $121.84 | 2024 | Austedo Xr |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $121.34 | 2024 | Xifaxan |
| Lilly USA, LLC | $120.12 | 2024 | Zepbound |
| Bayer Healthcare Pharmaceuticals INC. | $117.64 | 2025 | |
| Ultragenyx Pharmaceutical INC. | $116.28 | 2022 | |
| Novo Nordisk INC | $115.07 | 2024 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Idorsia Pharmaceuticals US INC | $96.40 | 2025 | Tryvio |
| Cvrx, INC. | $84.78 | 2022 | |
| Novartis Pharmaceuticals Corporation | $21.18 | 2023 | |
| Smith+Nephew, INC. | $19.72 | 2022 | |
| Axsome Therapeutics, INC. | $17.70 | 2025 | Auvelity |
| Boehringer Ingelheim Pharmaceuticals, INC. | $14.02 | 2023 | Jardiance |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Katrina Smith listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.